I.M. Sechenov First Moscow State Medical University (Sechenov University)
31. marts 2022 opdateret af: I.M. Sechenov First Moscow State Medical University
Optimization of Anticoagulant Therapy in Outpatient Practice
Single-institution uncontrolled open-label trial.
Studieoversigt
Status
Afsluttet
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
The single-institution uncontrolled open-label trial is to optimize the anticoagulant therapy in the out-patient practice.
The study embraces patients who are advised to take the anticoagulant therapy for some reasons. The study has two phases - a retrospective part and a concurrent part. At the first phase, researchers analyze the compliance with the anticoagulant therapy in the real clinical practice. At the concurrent phase, researchers conduct a single-institution uncontrolled open-label trial to evaluate the effectiveness, safety of the anticoagulant therapy and compliance with it at the antithrombotic therapy control ward, and estimate the glomerular filtration rate in patients taking the anticoagulant therapy.
Undersøgelsestype
Interventionel
Tilmelding (Faktiske)
1000
Fase
- Ikke anvendelig
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år til 120 år (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
- the age above 18
- indications for the anticoagulant therapy
- informed consent for inclusion into trials
Exclusion Criteria:
- denial to proceed in the trial
Non-inclusion criteria:
pregnancy and lactation
- Intracerebral hemorrhage within three preceding months
- severe mental disorders* which could possibly affect the anticoagulant therapy dosage schedule
- anemia and a decrease in Hb by ˂100 GM/DL*
- active gastroduodenal ulcer
- active bleeding during the preceding month
- other intensive bleeding instances as per the TIMI Score within three weeks before the inclusion
- severe hepatic impairment for over 10 points under the Child-Pugh Score
- oncology disease with the life expectancy less than one year
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Andet: anticoagulants arm
The study embraces patients who are advised to take the anticoagulant therapy (as per the European Society of Cardiology Guidelines).
The study evaluates the compliance with the anticoagulant therapy, safety and effectiveness, mortality
|
Patients who need anticoagulants were consulted by a cardiologist with subsequent recommendations
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
kidney compliance with the anticoagulant therapy and its safety and trends in the kidney function
Tidsramme: Evaluation of GFR, bleeding and thrombotic complications after 2 years
|
During a visit to the clinic, the patient will be surveyed and tested for the creatinine level
|
Evaluation of GFR, bleeding and thrombotic complications after 2 years
|
|
death due to any cause
Tidsramme: in six years after the anticoagulant therapy is prescribed
|
phone survey when patients are invited to the clinic
|
in six years after the anticoagulant therapy is prescribed
|
|
cardiovascular mortality
Tidsramme: Evaluation of GFR, bleeding and thrombotic complications and cardiac mortality after 2 years
|
Phone survey when patients are invited to the clinic.
The term cardiovascular mortality means a set of fatal heart attacks, fatal strokes, sudden death, fatal thromboembolism.
|
Evaluation of GFR, bleeding and thrombotic complications and cardiac mortality after 2 years
|
|
kidney function trend
Tidsramme: Evaluation of GFR, bleeding and thrombotic complications and cardiac mortality after 3 years
|
phone survey when patients are invited to the clinic for testing the creatinine level and further estimation of the glomerular filtration rate
|
Evaluation of GFR, bleeding and thrombotic complications and cardiac mortality after 3 years
|
|
intensive bleeding
Tidsramme: Evaluation of GFR, bleeding and thrombotic complications and cardiac mortality after 6 years
|
phone survey when patients are invited to the clinic.
|
Evaluation of GFR, bleeding and thrombotic complications and cardiac mortality after 6 years
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
frequency of thromboembolic events
Tidsramme: in 1-2-3-6 years after the anticoagulant therapy is prescribed
|
patients will be surveyed upon their visit to the clinic.
Thromboembolic events shall mean non-fatal embolic strokes, systemic embolism, acute coronary syndrome (to be corroborated with documents).
|
in 1-2-3-6 years after the anticoagulant therapy is prescribed
|
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
minor bleeding
Tidsramme: in 1-2-3-6 years after the anticoagulant therapy is prescribed
|
Minor bleeding shall mean any visually observed bleeding, including that discovered with various imaging methods, which cause a decrease in HB by less than 30 GM/DL or Ht by less than 9%.
|
in 1-2-3-6 years after the anticoagulant therapy is prescribed
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Efterforskere
- Ledende efterforsker: Zukhra Salpagarova, I.M. Sechenov First Moscow State Medical University (Sechenov University)
Publikationer og nyttige links
Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart
15. januar 2014
Primær færdiggørelse (Faktiske)
2. marts 2021
Studieafslutning (Faktiske)
2. marts 2021
Datoer for studieregistrering
Først indsendt
3. marts 2021
Først indsendt, der opfyldte QC-kriterier
31. marts 2022
Først opslået (Faktiske)
8. april 2022
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
8. april 2022
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
31. marts 2022
Sidst verificeret
1. marts 2021
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 678657
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
INGEN
IPD-planbeskrivelse
ethics committee requirement
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .